EVRYSDI: payments to doctors
Payments that named EVRYSDI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.6M
- Providers
- 1,169
- Transactions
- 3,632
- Average per transaction
- $439
The per-transaction average — $439 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,169 providers the average total is $1,364, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $1,281,432 | 80.4% |
| F. Hoffmann-la Roche AG | $139,775 | 8.8% |
| Genentech, Inc. | $126,065 | 7.9% |
| Roche Products Limited | $36,641 | 2.3% |
| Hoffmann-la Roche Limited | $10,860 | 0.7% |